Cancer Vaccine Stops Melanoma Return in 1,100 Patients

After decades of research, scientists have proven that personalized cancer vaccines can actually work in the real world.

Moderna and Merck announced that their experimental mRNA vaccine, intismeran, successfully stopped high-risk melanoma from returning in a study of over 1,100 patients. This marks the first time a personalized cancer vaccine has achieved success in a Phase 3 clinical trial, the final step before potential FDA approval.

The vaccine works completely differently from traditional cancer treatments. After doctors surgically remove a patient's melanoma, they analyze the tumor's unique genetic mutations. They then create a custom mRNA vaccine that trains the patient's immune system to recognize and attack those specific cancer markers.

Each patient receives a different vaccine tailored to their individual tumor. The process from biopsy to finished vaccine takes about six weeks.

In the trial, patients received either the personalized vaccine plus Keytruda (an existing immunotherapy drug) or Keytruda alone for about a year. The combination therapy kept cancer from returning longer than Keytruda by itself. It also stopped melanoma from spreading to other organs, meeting both primary and secondary goals of the study.

The approach essentially puts a patient's cancer mutations on a wanted list for their immune system. The vaccine alerts immune cells to these specific targets, while Keytruda helps amplify the body's natural cancer-fighting response.

This builds on earlier success. In a Phase 2 trial, the combination reduced the risk of melanoma returning or death by 49% compared to Keytruda alone.

Jane Healy, who leads oncology development at Merck, called the results highly encouraging. She noted that the combination therapy was well tolerated, with side effects similar to typical vaccines for other diseases.

The timing matters for melanoma patients. This aggressive skin cancer causes most skin cancer deaths despite representing only 1% of skin cancers. When melanoma returns, it usually happens within two to three years after initial treatment.

The Ripple Effect

Both companies are already testing the vaccine approach in other cancers, including non-small cell lung cancer, bladder cancer, and kidney cancer. The success in melanoma proves the concept could work across multiple cancer types.

Moderna aims to launch the vaccine by 2027 if regulators approve it. The achievement opens doors to a cancer treatment market valued at $240 billion.

Challenges remain before the vaccine reaches patients widely. Manufacturing a unique vaccine for each person requires complex, costly processes that will need to scale up dramatically.

But for now, the message is clear: training your own immune system to recognize and destroy your specific cancer is no longer just a promising idea.